Identification

Name
Salmeterol
Accession Number
DB00938  (APRD00277)
Type
Small Molecule
Groups
Approved
Description

Salmeterol is a long-acting beta2-adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.

Structure
Thumb
Synonyms
  • Salmaterol
  • Salmeterolum
External IDs
GR 33343 X / GR-33343-X / SN408D
Product Ingredients
IngredientUNIICASInChI Key
Salmeterol xinafoate6EW8Q962A594749-08-3XTZNCVSCVHTPAI-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Serevent (25mcg/actuation)Aerosol, metered25 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc1998-04-09Not applicableCanada
Serevent Diskhaler Disk (50mcg/dose)Powder50 mcgOral; Respiratory (inhalation)Glaxosmithkline Inc1998-02-11Not applicableCanada
Serevent DiskusPowder, metered50 ug/1Oral; Respiratory (inhalation)Glaxosmithkline Inc1997-12-01Not applicableUs
Serevent DiskusPowder, metered50 ug/1Oral; Respiratory (inhalation)Dispensing Solutions, Inc.1997-11-25Not applicableUs
Serevent DiskusPowder, metered50 ug/1Oral; Respiratory (inhalation)Glaxosmithkline Inc1997-11-25Not applicableUs
Serevent Diskus (50mcg/dose)Powder50 mcgRespiratory (inhalation)Glaxosmithkline Inc1998-04-01Not applicableCanada
Serevent- Aem 25mcg/aemAerosol, metered25 mcgOral; Respiratory (inhalation)Glaxo Canada Inc1994-12-311998-07-30Canada
Serevent-pwr 50mcg/blister PackPowder50 mcgOral; Respiratory (inhalation)Glaxo Canada Inc1994-12-31Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Advair 100 DiskusSalmeterol (50 mcg) + Fluticasone propionate (100 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair 125Salmeterol (25 mcg) + Fluticasone propionate (125 mcg)Aerosol, meteredRespiratory (inhalation)Glaxosmithkline Inc2001-12-21Not applicableCanada
Advair 250Salmeterol (25 mcg) + Fluticasone propionate (250 mcg)Aerosol, meteredRespiratory (inhalation)Glaxosmithkline Inc2001-12-21Not applicableCanada
Advair 250 DiskusSalmeterol (50 mcg) + Fluticasone propionate (250 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair 500 DiskusSalmeterol (50 mcg) + Fluticasone propionate (500 mcg)PowderRespiratory (inhalation)Glaxosmithkline Inc1999-09-24Not applicableCanada
Advair DiskusSalmeterol xinafoate (50 ug/1) + Fluticasone propionate (250 ug/1)PowderOral; Respiratory (inhalation)Physicians Total Care, Inc.2001-06-21Not applicableUs
Advair DiskusSalmeterol xinafoate (50 ug/1) + Fluticasone propionate (100 ug/1)PowderRespiratory (inhalation)Glaxosmithkline Inc2001-02-28Not applicableUs
Advair DiskusSalmeterol xinafoate (50 ug/1) + Fluticasone propionate (250 ug/1)PowderRespiratory (inhalation)Remedy Repack2017-05-15Not applicableUs
Advair DiskusSalmeterol xinafoate (50 ug/1) + Fluticasone propionate (100 ug/1)PowderRespiratory (inhalation)Rebel Distributors2001-02-28Not applicableUs
Advair DiskusSalmeterol xinafoate (50 ug/1) + Fluticasone propionate (250 ug/1)PowderRespiratory (inhalation)A S Medication Solutions2001-02-05Not applicableUs
International/Other Brands
Aeromax Diskus / Arial / Salmetedur / Serevent
Categories
UNII
2I4BC502BT
CAS number
89365-50-4
Weight
Average: 415.5656
Monoisotopic: 415.272258677
Chemical Formula
C25H37NO4
InChI Key
GIIZNNXWQWCKIB-UHFFFAOYSA-N
InChI
InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
IUPAC Name
4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)-2-(hydroxymethyl)phenol
SMILES
OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1

Pharmacology

Indication

For the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Associated Conditions
Pharmacodynamics

Salmeterol is a long acting beta2-adrenoceptor agonist (LABA), usually only prescribed for severe persistent asthma following previous treatment with a short-acting beta agonist such as salbutamol and is prescribed concurrently with a corticosteroid, such as beclometasone. The primary noticable difference of salmeterol to salbutamol is that the duration of action lasts approximately 12 hours in comparison with 4-6 hours of salbutamol. When used regularly every day as presecribed, inhaled salmeterol decreases the number and severity of asthma attacks. However, it is not for use for relieving an asthma attack that has already started. Inhaled salmeterol works like other beta 2-agonists, causing bronchodilatation by relaxing the smooth muscle in the airway so as to treat the exacerbation of asthma. Salmeterol is similar in action to formoterol, however formoterol has been demonstrated to have a faster onset of action than salmeterol as a result of a lower lipophilicity, and has also been demonstrated to be more potent - a 12 µg dose of formoterol has been demonstrated to be equivalent to a 50 µg dose of salmeterol.

Mechanism of action

Salmeterol's long, lipophilic side chain binds to exosites near beta(2)-receptors in the lungs and on bronchiolar smooth muscle, allowing the active portion of the molecule to remain at the receptor site, continually binding and releasing. Beta(2)-receptor stimulation in the lung causes relaxation of bronchial smooth muscle, bronchodilation, and increased bronchial airflow.

TargetActionsOrganism
ABeta-2 adrenergic receptor
agonist
Human
UBeta-1 adrenergic receptor
agonist
Human
UBeta-3 adrenergic receptor
agonist
Human
Absorption

Because of the small therapeutic dose, systemic levels of salmeterol are low or undetectable after inhalation of recommended doses.

Volume of distribution
Not Available
Protein binding

96%

Metabolism

Hepatic, metabolized by hydroxylation via CYP3A4

Route of elimination
Not Available
Half life

5.5 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include angina (chest pain), dizziness, dry mouth, fatigue, flu-like symptoms, headache, heart irregularities, high or low blood pressure, high blood sugar, insomnia, muscle cramps, nausea, nervousness, rapid heartbeat, seizures, and tremor. By the oral route, no deaths occurred in rats at 1,000 mg/kg (approximately 81,000 times the maximum recommended daily inhalation dose in adults and approximately 38,000 times the maximum recommended daily inhalation dose in children on a mg/m2 basis).

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbediterolThe risk or severity of adverse effects can be increased when Abediterol is combined with Salmeterol.Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Abexinostat.Investigational
AcebutololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Acebutolol.Approved, Investigational
AcepromazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Aceprometazine.Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Acrivastine.Approved
AlcaftadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Alcaftadine.Approved
AlclometasoneThe risk or severity of hypokalemia can be increased when Alclometasone is combined with Salmeterol.Approved
AldosteroneThe risk or severity of hypokalemia can be increased when Aldosterone is combined with Salmeterol.Experimental, Investigational
AlfuzosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Alfuzosin.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Alimemazine.Approved, Vet Approved
AlprenololAlprenolol may decrease the bronchodilatory activities of Salmeterol.Approved, Withdrawn
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Aluminium clofibrate.Experimental
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Salmeterol.Approved
AmcinonideThe risk or severity of hypokalemia can be increased when Amcinonide is combined with Salmeterol.Approved
AmifampridineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Amifampridine.Approved
AmineptineThe risk or severity of hypertension can be increased when Amineptine is combined with Salmeterol.Illicit, Withdrawn
AmiodaroneThe serum concentration of Salmeterol can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Amitriptyline.Approved
AmitriptylinoxideThe risk or severity of hypertension can be increased when Amitriptylinoxide is combined with Salmeterol.Approved, Investigational
AmodiaquineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Amodiaquine.Approved, Investigational
AmoxapineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Amoxapine.Approved
AmprenavirThe serum concentration of Salmeterol can be increased when it is combined with Amprenavir.Approved, Investigational
AnagrelideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Anagrelide.Approved
AnisodamineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Anisodamine.Investigational
AntazolineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Antazoline.Approved
ApalutamideThe serum concentration of Salmeterol can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Salmeterol.Approved, Investigational
AprepitantThe serum concentration of Salmeterol can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Arformoterol.Approved, Investigational
AripiprazoleThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Arotinolol.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Artemether.Approved
AsenapineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Asenapine.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Salmeterol can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Atenolol.Approved
AtomoxetineAtomoxetine may increase the tachycardic activities of Salmeterol.Approved
AtorvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Salmeterol is combined with Atosiban.Approved, Investigational
AzatadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Azatadine.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Azelastine.Approved
AzithromycinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Azithromycin.Approved
AzosemideThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Azosemide.Investigational
BambuterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Bambuterol.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Salmeterol.Approved, Investigational
BedaquilineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bedaquiline.Approved
BefunololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Befunolol.Experimental
BendroflumethiazideSalmeterol may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Salmeterol.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Benzatropine.Approved
BenzthiazideSalmeterol may increase the hypokalemic activities of Benzthiazide.Approved
Benzylpenicilloyl PolylysineSalmeterol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Besifloxacin.Approved
BetahistineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Betahistine.Approved, Investigational
BetamethasoneThe risk or severity of hypokalemia can be increased when Betamethasone is combined with Salmeterol.Approved, Vet Approved
BetaxololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Betaxolol.Approved, Investigational
BevantololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Bevantolol.Approved
BezafibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Bezafibrate.Approved, Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bilastine.Approved, Investigational
BisoprololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Bitolterol is combined with Salmeterol.Withdrawn
BoceprevirThe serum concentration of Salmeterol can be increased when it is combined with Boceprevir.Approved, Withdrawn
BopindololBopindolol may decrease the bronchodilatory activities of Salmeterol.Approved
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salmeterol.Approved, Investigational
BosentanThe serum concentration of Salmeterol can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Brexpiprazole.Approved, Investigational
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Brompheniramine.Approved
BucindololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Bucindolol.Investigational
BuclizineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Buclizine.Approved
BudesonideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Salmeterol.Approved
BufuralolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Bumetanide.Approved
BunazosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Bunazosin.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Salmeterol.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Buserelin.Approved, Investigational
ButriptylineThe risk or severity of hypertension can be increased when Butriptyline is combined with Salmeterol.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
CarbamazepineThe metabolism of Salmeterol can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Carbinoxamine.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Salmeterol.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Salmeterol.Approved
CarvedilolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Carvedilol.Approved, Investigational
CeliprololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Salmeterol can be increased when it is combined with Ceritinib.Approved
CerivastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Cerivastatin.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cetirizine.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorcyclizine.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideSalmeterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorphenamine.Approved
ChlorpromazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneSalmeterol may increase the hypokalemic activities of Chlorthalidone.Approved
CiclesonideThe risk or severity of hypokalemia can be increased when Ciclesonide is combined with Salmeterol.Approved, Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cilostazol.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cinnarizine.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ciprofibrate.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Salmeterol can be increased when it is combined with Clarithromycin.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobetasolThe risk or severity of hypokalemia can be increased when Clobetasol is combined with Salmeterol.Approved, Investigational
Clobetasol propionateThe risk or severity of hypokalemia can be increased when Clobetasol propionate is combined with Salmeterol.Approved
ClobetasoneThe risk or severity of hypokalemia can be increased when Clobetasone is combined with Salmeterol.Approved
ClocortoloneThe risk or severity of hypokalemia can be increased when Clocortolone is combined with Salmeterol.Approved
ClofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Clofibrate.Approved, Investigational
ClofibrideThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Clofibride.Experimental
ClomipramineThe risk or severity of hypertension can be increased when Clomipramine is combined with Salmeterol.Approved, Investigational, Vet Approved
CloprednolThe risk or severity of hypokalemia can be increased when Cloprednol is combined with Salmeterol.Experimental
CloranololCloranolol may decrease the bronchodilatory activities of Salmeterol.Experimental
ClotrimazoleThe serum concentration of Salmeterol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Clozapine.Approved
CobicistatThe serum concentration of Salmeterol can be increased when it is combined with Cobicistat.Approved
CocaineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Salmeterol.Approved, Investigational
CorticotropinThe risk or severity of hypokalemia can be increased when Corticotropin is combined with Salmeterol.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of hypokalemia can be increased when Cortisone acetate is combined with Salmeterol.Approved, Investigational
CortivazolThe risk or severity of hypokalemia can be increased when Cortivazol is combined with Salmeterol.Investigational
CrizotinibThe serum concentration of Salmeterol can be increased when it is combined with Crizotinib.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when Salmeterol is combined with CUDC-101.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when Salmeterol is combined with CUDC-907.Investigational
CurcuminThe serum concentration of Salmeterol can be increased when it is combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of hypertension can be increased when Cyclobenzaprine is combined with Salmeterol.Approved
CyclopenthiazideSalmeterol may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Salmeterol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Salmeterol can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe serum concentration of Salmeterol can be increased when it is combined with Danazol.Approved
DapiprazoleThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Dapiprazole.Approved
DarunavirThe serum concentration of Salmeterol can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Salmeterol can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Salmeterol can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of hypokalemia can be increased when Deflazacort is combined with Salmeterol.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Degarelix.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Delamanid.Approved, Investigational
DelavirdineThe serum concentration of Salmeterol can be increased when it is combined with Delavirdine.Approved
DesfluraneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Desflurane.Approved
DesipramineThe risk or severity of hypertension can be increased when Desipramine is combined with Salmeterol.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Desloratadine.Approved, Investigational
DesonideThe risk or severity of hypokalemia can be increased when Desonide is combined with Salmeterol.Approved, Investigational
DesoximetasoneThe risk or severity of hypokalemia can be increased when Desoximetasone is combined with Salmeterol.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Salmeterol.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Salmeterol.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of hypokalemia can be increased when Dexamethasone isonicotinate is combined with Salmeterol.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dexbrompheniramine.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dexchlorpheniramine.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dexchlorpheniramine maleate.Approved
DibenzepinThe risk or severity of hypertension can be increased when Dibenzepin is combined with Salmeterol.Experimental
DiflorasoneThe risk or severity of hypokalemia can be increased when Diflorasone is combined with Salmeterol.Approved
DifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Difloxacin.Vet Approved
DifluocortoloneThe risk or severity of hypokalemia can be increased when Difluocortolone is combined with Salmeterol.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of hypokalemia can be increased when Difluprednate is combined with Salmeterol.Approved
DihydroergocornineDihydroergocornine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
DihydroergocristineDihydroergocristine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved, Experimental
DihydroergocryptineDihydroergocryptine may increase the hypertensive and vasoconstricting activities of Salmeterol.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved, Investigational
DiltiazemThe serum concentration of Salmeterol can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of hypertension can be increased when Dimetacrine is combined with Salmeterol.Approved, Withdrawn
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Diphenhydramine.Approved, Investigational
DipivefrinThe risk or severity of adverse effects can be increased when Salmeterol is combined with Dipivefrin.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Dobutamine.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dofetilide.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Dolasetron.Approved, Investigational
DomperidoneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Domperidone.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Donepezil.Approved
DosulepinThe risk or severity of hypertension can be increased when Dosulepin is combined with Salmeterol.Approved
DoxazosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Doxazosin.Approved
DoxepinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Doxofylline is combined with Salmeterol.Approved, Investigational
DoxycyclineThe serum concentration of Salmeterol can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Doxylamine.Approved, Vet Approved
DronedaroneThe serum concentration of Salmeterol can be increased when it is combined with Dronedarone.Approved
DroperidolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Droperidol.Approved, Vet Approved
DroxidopaThe risk or severity of adverse effects can be increased when Salmeterol is combined with Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the tachycardic activities of Salmeterol.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ebastine.Approved, Investigational
EfavirenzThe serum concentration of Salmeterol can be increased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Eliglustat.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Emedastine.Approved
EnoxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Enoxacin.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Entinostat.Investigational
EnzalutamideThe serum concentration of Salmeterol can be decreased when it is combined with Enzalutamide.Approved
EpanololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Salmeterol is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Epinephrine.Approved, Vet Approved
EpitizideSalmeterol may increase the hypokalemic activities of Epitizide.Experimental
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Salmeterol can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Esatenolol.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Escitalopram.Approved, Investigational
EsmololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Esmolol.Approved
Etacrynic acidThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Etafedrine.Approved
EtofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Etofibrate.Approved
EtravirineThe serum concentration of Salmeterol can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ezogabine.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Salmeterol.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Felbamate.Approved
FenofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Fenofibrate.Approved
Fenofibric acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Fenofibric acid.Approved
FenoterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Fenoterol.Approved, Investigational
FexofenadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fexofenadine.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fingolimod.Approved, Investigational
FlecainideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Flecainide.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fleroxacin.Approved
FlucloroloneThe risk or severity of hypokalemia can be increased when Fluclorolone is combined with Salmeterol.Experimental
FluconazoleThe serum concentration of Salmeterol can be increased when it is combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of hypokalemia can be increased when Fludrocortisone is combined with Salmeterol.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of hypokalemia can be increased when Flumethasone is combined with Salmeterol.Approved, Vet Approved
FlunisolideThe risk or severity of hypokalemia can be increased when Flunisolide is combined with Salmeterol.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of hypokalemia can be increased when Fluocinolone Acetonide is combined with Salmeterol.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of hypokalemia can be increased when Fluocinonide is combined with Salmeterol.Approved, Investigational
FluocortinThe risk or severity of hypokalemia can be increased when Fluocortin is combined with Salmeterol.Experimental
FluocortoloneThe risk or severity of hypokalemia can be increased when Fluocortolone is combined with Salmeterol.Approved, Withdrawn
FluorometholoneThe risk or severity of hypokalemia can be increased when Fluorometholone is combined with Salmeterol.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of hypokalemia can be increased when Fluperolone is combined with Salmeterol.Experimental
FluprednideneThe risk or severity of hypokalemia can be increased when Fluprednidene is combined with Salmeterol.Approved, Withdrawn
FluprednisoloneThe risk or severity of hypokalemia can be increased when Fluprednisolone is combined with Salmeterol.Approved
FlurandrenolideThe risk or severity of hypokalemia can be increased when Flurandrenolide is combined with Salmeterol.Approved
FluticasoneThe risk or severity of hypokalemia can be increased when Fluticasone is combined with Salmeterol.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of hypokalemia can be increased when Fluticasone furoate is combined with Salmeterol.Approved
Fluticasone propionateThe risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Salmeterol.Approved
FluvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Salmeterol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormocortalThe risk or severity of hypokalemia can be increased when Formocortal is combined with Salmeterol.Experimental
FormoterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Salmeterol can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Salmeterol can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Salmeterol.Approved
FosphenytoinThe metabolism of Salmeterol can be increased when combined with Fosphenytoin.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Salmeterol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Salmeterol can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Gadobenic acid.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Salmeterol.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Gatifloxacin.Approved, Investigational
GemfibrozilThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Gemfibrozil.Approved
GemifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Gemifloxacin.Approved, Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Givinostat.Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Goserelin.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Granisetron.Approved, Investigational
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Grepafloxacin.Approved, Investigational, Withdrawn
HalcinonideThe risk or severity of hypokalemia can be increased when Halcinonide is combined with Salmeterol.Approved, Investigational, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Halofantrine.Approved
HalometasoneThe risk or severity of hypokalemia can be increased when Halometasone is combined with Salmeterol.Experimental
HaloperidolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Haloperidol.Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Salmeterol.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Hexoprenaline.Approved, Withdrawn
HistrelinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Histrelin.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Salmeterol.Experimental
HydrochlorothiazideSalmeterol may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Salmeterol.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of hypokalemia can be increased when Hydrocortisone aceponate is combined with Salmeterol.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Salmeterol.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Salmeterol.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of hypokalemia can be increased when Hydrocortisone probutate is combined with Salmeterol.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of hypokalemia can be increased when Hydrocortisone succinate is combined with Salmeterol.Approved
Hydrocortisone valerateThe risk or severity of hypokalemia can be increased when Hydrocortisone valerate is combined with Salmeterol.Approved, Vet Approved
HydroflumethiazideSalmeterol may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Hydroxychloroquine.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Salmeterol.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Salmeterol.Approved, Investigational
IbutilideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ibutilide.Approved
IdelalisibThe serum concentration of Salmeterol can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Iloperidone.Approved
ImatinibThe serum concentration of Salmeterol can be increased when it is combined with Imatinib.Approved
ImipramineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Imipramine.Approved
Imipramine oxideThe risk or severity of hypertension can be increased when Imipramine oxide is combined with Salmeterol.Experimental
IndacaterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Indacaterol.Approved
IndapamideSalmeterol may increase the hypokalemic activities of Indapamide.Approved
IndenololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Indenolol.Withdrawn
IndinavirThe serum concentration of Salmeterol can be increased when it is combined with Indinavir.Approved
IndoraminThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Indoramin.Withdrawn
IprindoleThe risk or severity of hypertension can be increased when Iprindole is combined with Salmeterol.Experimental
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Salmeterol.Withdrawn
IsavuconazoleThe serum concentration of Salmeterol can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Salmeterol can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Salmeterol.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Isoetarine.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Salmeterol.Approved, Vet Approved
IsoniazidThe serum concentration of Salmeterol can be increased when it is combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Isoprenaline.Approved, Investigational
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Salmeterol.Approved, Investigational
ItraconazoleThe serum concentration of Salmeterol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Salmeterol can be increased when it is combined with Ivacaftor.Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ivosidenib.Approved, Investigational
KetoconazoleThe serum concentration of Salmeterol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetotifenThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ketotifen.Approved
LabetalolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Labetalol.Approved
LandiololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Landiolol.Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lapatinib.Approved, Investigational
LenvatinibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lenvatinib.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Leuprolide.Approved, Investigational
LevobetaxololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Levobetaxolol.Approved, Investigational
LevobunololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Levobunolol.Approved
LevocabastineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levocetirizine.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Salmeterol.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Salmeterol.Approved, Investigational
LisurideLisuride may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lithium cation.Experimental
LofepramineThe risk or severity of hypertension can be increased when Lofepramine is combined with Salmeterol.Experimental
LomefloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lomefloxacin.Approved, Investigational
LopinavirThe serum concentration of Salmeterol can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Loratadine.Approved, Investigational
LorpiprazoleThe serum concentration of Salmeterol can be increased when it is combined with Lorpiprazole.Approved
LoteprednolThe risk or severity of hypokalemia can be increased when Loteprednol is combined with Salmeterol.Approved
LovastatinThe serum concentration of Salmeterol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Loxapine.Approved
LuliconazoleThe serum concentration of Salmeterol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Salmeterol can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Lumefantrine.Approved
Lysergic Acid DiethylamideLysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Salmeterol.Illicit, Investigational, Withdrawn
MacimorelinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Macimorelin.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Salmeterol.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Salmeterol.Withdrawn
MedrysoneThe risk or severity of hypokalemia can be increased when Medrysone is combined with Salmeterol.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Salmeterol.Approved, Investigational
MelengestrolThe risk or severity of hypokalemia can be increased when Melengestrol is combined with Salmeterol.Vet Approved
MelitracenThe risk or severity of hypertension can be increased when Melitracen is combined with Salmeterol.Experimental, Investigational
MepindololMepindolol may decrease the bronchodilatory activities of Salmeterol.Experimental
MeprednisoneThe risk or severity of hypokalemia can be increased when Meprednisone is combined with Salmeterol.Approved, Investigational
MepyramineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mepyramine.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mequitazine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mesoridazine.Approved, Investigational
MetergolineMetergoline may increase the hypertensive and vasoconstricting activities of Salmeterol.Experimental
MethadoneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Methadone.Approved
MethotrimeprazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Methotrimeprazine.Approved, Investigational
MethyclothiazideSalmeterol may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Salmeterol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
MethylprednisoloneThe risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Salmeterol.Approved, Vet Approved
MethysergideMethysergide may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved
MetipranololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Metipranolol.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Metoclopramide.Approved, Investigational
MetolazoneSalmeterol may increase the hypokalemic activities of Metolazone.Approved
MetoprololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Metoprolol.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Salmeterol.Approved
MevastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Mevastatin.Experimental
MibefradilThe serum concentration of Salmeterol can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Salmeterol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Salmeterol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Salmeterol.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Salmeterol.Approved
MirabegronThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mirabegron.Approved
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Salmeterol.Approved
MitotaneThe serum concentration of Salmeterol can be decreased when it is combined with Mitotane.Approved
MocetinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Mocetinostat.Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Salmeterol.Approved, Investigational
ModafinilThe serum concentration of Salmeterol can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Salmeterol.Approved
MometasoneThe risk or severity of hypokalemia can be increased when Mometasone is combined with Salmeterol.Approved, Vet Approved
Mometasone furoateThe risk or severity of hypokalemia can be increased when Mometasone furoate is combined with Salmeterol.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Moxifloxacin.Approved, Investigational
NadololNadolol may decrease the bronchodilatory activities of Salmeterol.Approved
NafcillinThe serum concentration of Salmeterol can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Nalidixic Acid.Approved, Investigational
NaloxoneThe serum concentration of Salmeterol can be increased when it is combined with Naloxone.Approved, Vet Approved
NebivololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Salmeterol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Salmeterol can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Nemonoxacin.Investigational
NetupitantThe serum concentration of Salmeterol can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Salmeterol can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Salmeterol.Withdrawn
NicardipineThe serum concentration of Salmeterol can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineNicergoline may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved, Investigational
NiguldipineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Niguldipine.Experimental
NilotinibThe serum concentration of Salmeterol can be increased when it is combined with Nilotinib.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Norepinephrine.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Norfloxacin.Approved
NortriptylineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Nortriptyline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Salmeterol.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Salmeterol.Approved, Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ofloxacin.Approved
OlanzapineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Salmeterol can be increased when it is combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Olodaterol.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Olopatadine.Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ondansetron.Approved
OpipramolThe risk or severity of hypertension can be increased when Opipramol is combined with Salmeterol.Investigational
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Salmeterol.Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Salmeterol can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Oxaliplatin.Approved, Investigational
OxaprotilineThe risk or severity of hypertension can be increased when Oxaprotiline is combined with Salmeterol.Experimental
OxatomideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Oxatomide.Investigational
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Oxolinic acid.Experimental
OxprenololOxprenolol may decrease the bronchodilatory activities of Salmeterol.Approved
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Salmeterol.Approved, Vet Approved
PalbociclibThe serum concentration of Salmeterol can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Paliperidone.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Papaverine.Approved, Investigational
ParamethasoneThe risk or severity of hypokalemia can be increased when Paramethasone is combined with Salmeterol.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Salmeterol.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Salmeterol.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pasireotide.Approved
PazopanibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pefloxacin.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Salmeterol.Approved, Investigational
PentamidineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pentamidine.Approved, Investigational
PentobarbitalThe metabolism of Salmeterol can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerflutrenThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Perflutren.Approved
PergolidePergolide may increase the hypertensive and vasoconstricting activities of Salmeterol.Approved, Investigational, Vet Approved, Withdrawn
PF-00610355The risk or severity of adverse effects can be increased when Salmeterol is combined with PF-00610355.Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Salmeterol.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Salmeterol.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pheniramine.Approved
PhenobarbitalThe metabolism of Salmeterol can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Phenoxybenzamine.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Salmeterol.Withdrawn
PhentolamineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Phentolamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Salmeterol can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pimozide.Approved
PindololPindolol may decrease the bronchodilatory activities of Salmeterol.Approved, Investigational
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pipemidic acid.Experimental
PirbuterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Pirbuterol.Approved
PiretanideThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Piretanide.Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salmeterol.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Piromidic acid.Experimental
PitavastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Pitavastatin.Approved
PitolisantThe serum concentration of Salmeterol can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Salmeterol.Withdrawn
PizotifenThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Pizotifen.Approved
PolythiazideSalmeterol may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Salmeterol can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PracinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Pracinostat.Investigational
PractololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Practolol.Approved
PravastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Pravastatin.Approved
PrazosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Prazosin.Approved
PrednicarbateThe risk or severity of hypokalemia can be increased when Prednicarbate is combined with Salmeterol.Approved, Investigational
PrednisoloneThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Salmeterol.Approved, Vet Approved
PrednisoneThe risk or severity of hypokalemia can be increased when Prednisone is combined with Salmeterol.Approved, Vet Approved
PrednylideneThe risk or severity of hypokalemia can be increased when Prednylidene is combined with Salmeterol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Primaquine.Approved
PrimidoneThe metabolism of Salmeterol can be increased when combined with Primidone.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Probucol.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Procainamide.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Procaterol.Approved, Investigational
PromazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Promethazine.Approved, Investigational
PropafenoneThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Propafenone.Approved
PropericiazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Propericiazine.Approved, Investigational
PropiomazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Propiomazine.Approved
PropiverineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Propiverine.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Salmeterol.Approved, Investigational, Vet Approved
PropranololPropranolol may decrease the bronchodilatory activities of Salmeterol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe risk or severity of hypertension can be increased when Protriptyline is combined with Salmeterol.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Prulifloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Quetiapine.Approved
QuinethazoneSalmeterol may increase the hypokalemic activities of Quinethazone.Approved
QuinidineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Quinine.Approved
QuinupramineThe risk or severity of hypertension can be increased when Quinupramine is combined with Salmeterol.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Racepinephrine.Approved
RanolazineThe risk or severity of QTc prolongation can be increased when Ranolazine is combined with Salmeterol.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Salmeterol.Approved
RibociclibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Ricolinostat.Investigational
RifampicinThe metabolism of Salmeterol can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Salmeterol can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Salmeterol can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Salmeterol can be increased when combined with Rifaximin.Approved, Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rilpivirine.Approved
RimexoloneThe risk or severity of hypokalemia can be increased when Rimexolone is combined with Salmeterol.Approved
RisperidoneThe serum concentration of Salmeterol can be increased when it is combined with Risperidone.Approved, Investigational
RitodrineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Salmeterol can be increased when it is combined with Ritonavir.Approved, Investigational
RomidepsinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Romidepsin.Approved, Investigational
RonifibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Ronifibrate.Experimental
RosoxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Rosuvastatin.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Roxithromycin.Approved, Investigational, Withdrawn
RufloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rufloxacin.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Rupatadine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Safinamide is combined with Salmeterol.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Salmeterol.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe serum concentration of Salmeterol can be increased when it is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Sarilumab.Approved, Investigational
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Salmeterol.Approved, Investigational, Vet Approved
SertralineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sertraline.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sevoflurane.Approved, Vet Approved
SibutramineSibutramine may increase the tachycardic activities of Salmeterol.Approved, Illicit, Investigational, Withdrawn
SilodosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Silodosin.Approved
SiltuximabThe serum concentration of Salmeterol can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Salmeterol can be increased when it is combined with Simeprevir.Approved
SimfibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Simfibrate.Experimental
SimvastatinThe risk or severity of myopathy and rhabdomyolysis can be increased when Salmeterol is combined with Simvastatin.Approved
SitafloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sitafloxacin.Experimental, Investigational
SolifenacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Solifenacin.Approved
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Salmeterol.Approved, Investigational
SotalolSotalol may decrease the bronchodilatory activities of Salmeterol.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sparfloxacin.Approved, Investigational
SpironolactoneThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Spironolactone.Approved
St. John's WortThe serum concentration of Salmeterol can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Salmeterol can be increased when it is combined with Stiripentol.Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulfamethoxazole.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sultopride.Experimental
SunitinibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sunitinib.Approved, Investigational
TalinololThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Talinolol.Investigational
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Salmeterol.Approved
TamsulosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Tamsulosin.Approved, Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Tandutinib.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Technetium Tc-99m ciprofloxacin.Investigational
TelavancinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Telavancin.Approved
TelithromycinThe serum concentration of Salmeterol can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Temafloxacin.Withdrawn
TerazosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Terazosin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Salmeterol is combined with Terbutaline.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Terfenadine.Approved, Withdrawn
TergurideTerguride may increase the hypertensive and vasoconstricting activities of Salmeterol.Experimental
TerlipressinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Terlipressin.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Terodiline.Experimental
TertatololTertatolol may decrease the bronchodilatory activities of Salmeterol.Experimental
TetrabenazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Tetrabenazine.Approved, Investigational
ThioproperazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Thioproperazine.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Thiothixene.Approved
TianeptineThe risk or severity of hypertension can be increased when Tianeptine is combined with Salmeterol.Approved, Investigational
TimololTimolol may decrease the bronchodilatory activities of Salmeterol.Approved
TixocortolThe risk or severity of hypokalemia can be increased when Tixocortol is combined with Salmeterol.Approved, Withdrawn
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Salmeterol.Approved, Investigational
TocilizumabThe serum concentration of Salmeterol can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Tolazoline.Approved, Vet Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Salmeterol.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Tolterodine.Approved, Investigational
TorasemideThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Torasemide.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Toremifene.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Salmeterol.Approved, Investigational
TrazodoneThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Trazodone.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Salmeterol.Approved, Investigational
TriamcinoloneThe risk or severity of hypokalemia can be increased when Triamcinolone is combined with Salmeterol.Approved, Vet Approved
TrichlormethiazideSalmeterol may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Trifluoperazine.Approved, Investigational
TrilostaneThe risk or severity of hypokalemia can be increased when Trilostane is combined with Salmeterol.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Trimazosin.Experimental
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Salmeterol.Approved, Vet Approved
TrimipramineThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Trimipramine.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Triprolidine.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Triptorelin.Approved, Vet Approved
TroleandomycinThe serum concentration of Salmeterol can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TucidinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Tucidinostat.Investigational
UlobetasolThe risk or severity of hypokalemia can be increased when Ulobetasol is combined with Salmeterol.Approved
UrapidilThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Urapidil.Investigational
Valproic AcidThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Valproic Acid.Approved, Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Vandetanib.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Salmeterol.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Salmeterol.Approved
VerapamilThe serum concentration of Salmeterol can be increased when it is combined with Verapamil.Approved
VilanterolThe risk or severity of adverse effects can be increased when Salmeterol is combined with Vilanterol.Approved
VoriconazoleThe serum concentration of Salmeterol can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Vorinostat.Approved, Investigational
ZiprasidoneThe serum concentration of Salmeterol can be increased when it is combined with Ziprasidone.Approved
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Panayiotis Procopiou, "Novel process for preparing salmeterol." U.S. Patent US20030162840, issued August 28, 2003.

US20030162840
General References
  1. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE: Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006 Jun 20;144(12):904-12. Epub 2006 Jun 5. [PubMed:16754916]
External Links
Human Metabolome Database
HMDB0015073
KEGG Drug
D05792
KEGG Compound
C07241
PubChem Compound
5152
PubChem Substance
46508024
ChemSpider
4968
BindingDB
25771
ChEBI
64064
ChEMBL
CHEMBL1263
Therapeutic Targets Database
DAP000947
PharmGKB
PA451300
IUPHAR
559
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Salmeterol
ATC Codes
R03AK06 — Salmeterol and fluticasoneR03AK12 — Salmeterol and budesonideR03AC12 — Salmeterol
AHFS Codes
  • 12:12.08.12 — Selective Beta 2-adrenergic Agonists
  • 12:12.00 — Sympathomimetic (Adrenergic) Agents
FDA label
Download (132 KB)
MSDS
Download (51 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentSpinal Cord Injuries (SCI)1
1CompletedNot AvailableAsthma Bronchial1
1CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD) / Smoke-related Lung Diseases1
1CompletedScreeningPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)3
1CompletedTreatmentAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
2Active Not RecruitingTreatmentAsthma Bronchial1
2CompletedTreatmentAbdominal Contour Defects1
2CompletedTreatmentAsthma Bronchial7
2CompletedTreatmentAsthma Bronchial / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentCentral Abdominal Bulging1
2CompletedTreatmentChronic Lung Diseases / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)5
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
2CompletedTreatmentPeriumbilical Subcutaneous Adipose Tissue Reduction1
2CompletedTreatmentPulmonary Disease, Chronic Obstructive6
2CompletedTreatmentSubmental Fat1
2RecruitingTreatmentAsthma Bronchial1
2WithdrawnNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
3Active Not RecruitingTreatmentAsthma Bronchial1
3Active Not RecruitingTreatmentCentral Abdominal Bulging1
3CompletedPreventionAsthma, Exercise-Induced1
3CompletedTreatmentAsthma Bronchial14
3CompletedTreatmentBronchial Asthma1
3CompletedTreatmentCentral Abdominal Bulging1
3CompletedTreatmentChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)11
3CompletedTreatmentExercised Induced Asthma1
3CompletedTreatmentPulmonary Disease, Chronic Obstructive8
3Enrolling by InvitationNot AvailableCentral Abdominal Bulging1
3Not Yet RecruitingTreatmentAsthma Bronchial1
3RecruitingTreatmentAsthma Bronchial4
3RecruitingTreatmentAsthma, Allergic1
3TerminatedTreatmentPulmonary Disease, Chronic Obstructive2
3Unknown StatusTreatmentPulmonary Disease, Chronic Obstructive2
3WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD)3
3WithdrawnTreatmentPulmonary Disease, Chronic Obstructive1
4Active Not RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
4CompletedNot AvailableAsthma Bronchial1
4CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
4CompletedBasic SciencePharmacokinetics in Healthy Young Men1
4CompletedDiagnosticAsthmatic Smokers / Non-asthmatic Smokers1
4CompletedOtherAsthma Bronchial1
4CompletedOtherPulmonary Disease, Chronic Obstructive1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAsthma Bronchial11
4CompletedTreatmentAsthma Bronchial / Bronchial Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)6
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Depression1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive2
4CompletedTreatmentPulmonary Disease, Chronic Obstructive9
4RecruitingTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4TerminatedTreatmentAsthma Bronchial2
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
4Unknown StatusTreatmentAsthma Bronchial1
4Unknown StatusTreatmentChronic Bronchitis / Chronic Obstructive Pulmonary Disease (COPD) / Emphysema1
4Unknown StatusTreatmentPercentage of Annual Acute Exacerbation / Quality of Life1
4WithdrawnTreatmentAsthma Bronchial1
Not AvailableCompletedNot AvailableAsthma Bronchial3
Not AvailableCompletedNot AvailableAsthma Bronchial / BMI >30 kg/m21
Not AvailableCompletedNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailablePulmonary Disease, Chronic Obstructive2
Not AvailableCompletedNot AvailableRespiratory Disorders2
Not AvailableCompletedBasic ScienceAsthma, Allergic1
Not AvailableCompletedBasic ScienceBronchodilator Agents / Chronic Obstructive Pulmonary Disease (COPD) / Salmeterol / Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients1
Not AvailableCompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentAsthma Bronchial4
Not AvailableCompletedTreatmentAsthma, Allergic / Mild, Allergic Asthma1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingNot AvailableAsthma Bronchial1
Not AvailableRecruitingTreatmentChronic Lung Diseases / Medication Compliance1
Not AvailableSuspendedTreatmentCystic Fibrosis (CF)1
Not AvailableTerminatedTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentAsthma Bronchial1
Not AvailableUnknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableWithdrawnNot AvailableChronic Obstructive Pulmonary Disease (COPD) / Sleep disorders and disturbances1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Glaxo group ltd dba glaxosmithkline
Packagers
  • A-S Medication Solutions LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • GlaxoSmithKline Inc.
  • Lake Erie Medical and Surgical Supply
  • Rebel Distributors Corp.
Dosage forms
FormRouteStrength
Aerosol, meteredRespiratory (inhalation)
PowderOral; Respiratory (inhalation)
PowderRespiratory (inhalation)
Powder, meteredRespiratory (inhalation)
PowderOral; Respiratory (inhalation)50 mcg
Powder, meteredOral; Respiratory (inhalation)50 ug/1
PowderRespiratory (inhalation)50 mcg
Aerosol, meteredOral; Respiratory (inhalation)25 mcg
Prices
Unit descriptionCostUnit
Serevent Diskus 60 50 mcg/dose Powder Inhaler182.81USD inhaler
Serevent Diskhaler Device6.15USD device
Serevent 50 mcg/dose Disk4.21USD disk
Serevent diskus 50 mcg3.71USD each
Serevent Diskus 50 mcg/dose Metered Inhalation Powder1.05USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5590645No1994-03-012011-03-01Us
CA2165830No2005-04-262014-06-30Canada
CA1335999No1995-06-202012-06-20Canada
US5873360Yes1996-08-232016-08-23Us
US6446627No1997-12-182017-12-18Us
US6743413Yes2001-12-012021-12-01Us
US6938796Yes1998-07-162018-07-16Us
US6997349Yes1998-07-162018-07-16Us
US6431168Yes1998-12-082018-12-08Us
US7107986Yes1998-12-062018-12-06Us
US7500444Yes2006-08-262026-08-26Us
US6315173Yes1998-06-232018-06-23Us
US7143908Yes1998-07-162018-07-16Us
US6170717Yes1998-06-232018-06-23Us
US7350676Yes1999-02-242019-02-24Us
US7832351Yes2003-12-192023-12-19Us
US6161724Yes1998-07-162018-07-16Us
US6510969Yes1998-06-232018-06-23Us
US6966467Yes1998-06-232018-06-23Us
US6435372Yes1998-07-162018-07-16Us
US6871646No2001-06-232021-06-23Us
US8978966No2012-01-132032-01-13Us
US6701917No2001-06-232021-06-23Us
US7540282No2003-05-062023-05-06Us
US6748947No2001-06-232021-06-23Us
US8006690No2001-06-232021-06-23Us
US6718972No2001-06-232021-06-23Us
US9216260No2011-06-282031-06-28Us
US8651103No2008-03-262028-03-26Us
US9463288No2005-05-192025-05-19Us
US8714149No2012-02-252032-02-25Us
US9616024No2004-09-012024-09-01Us
US9066957No2014-10-062034-10-06Us
US9415008No2014-10-062034-10-06Us
US9731087No2011-05-182031-05-18Us
US9861771No2000-10-112020-10-11Us
US9987229No2004-09-012024-09-01Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)75.5-76.5 °CNot Available
water solubilitySparingly solubleNot Available
logP4.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00226 mg/mLALOGPS
logP3.82ALOGPS
logP3.61ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)10.12ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.95 Å2ChemAxon
Rotatable Bond Count16ChemAxon
Refractivity122.39 m3·mol-1ChemAxon
Polarizability50.6 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8516
Blood Brain Barrier-0.8862
Caco-2 permeable-0.6968
P-glycoprotein substrateSubstrate0.7767
P-glycoprotein inhibitor IInhibitor0.539
P-glycoprotein inhibitor IIInhibitor0.7663
Renal organic cation transporterNon-inhibitor0.6106
CYP450 2C9 substrateNon-substrate0.8
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5937
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9099
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.6121
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8618
Ames testNon AMES toxic0.807
CarcinogenicityNon-carcinogens0.9378
BiodegradationReady biodegradable0.5587
Rat acute toxicity2.0830 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.741
hERG inhibition (predictor II)Inhibitor0.7149
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0001900000-3c44a8f19551abbbb83a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001j-0029000000-43896c08fd5ce2a060e8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-4972000000-23117c7d5dc844d67897
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-6910000000-2afb08aff0a51fff0532
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-9800000000-5575125dd87cfbd258a8
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00kb-0229500000-3598d6091893d5b1aa38

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzyl alcohols. These are organic compounds containing the phenylmethanol substructure.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzyl alcohols
Direct Parent
Benzyl alcohols
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Dialkyl ethers / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Benzyl alcohol / Phenol / Aralkylamine / 1-hydroxy-2-unsubstituted benzenoid / Secondary alcohol / 1,2-aminoalcohol / Dialkyl ether / Secondary aliphatic amine / Ether / Secondary amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary alcohol, phenols, secondary amino compound, ether, primary alcohol (CHEBI:64064)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Rong Y, Arbabian M, Thiriot DS, Seibold A, Clark RB, Ruoho AE: Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. Biochemistry. 1999 Aug 31;38(35):11278-86. [PubMed:10471277]
  2. Finney PA, Donnelly LE, Belvisi MG, Chuang TT, Birrell M, Harris A, Mak JC, Scorer C, Barnes PJ, Adcock IM, Giembycz MA: Chronic systemic administration of salmeterol to rats promotes pulmonary beta(2)-adrenoceptor desensitization and down-regulation of G(s alpha). Br J Pharmacol. 2001 Mar;132(6):1261-70. [PubMed:11250877]
  3. Green SA, Rathz DA, Schuster AJ, Liggett SB: The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol. 2001 Jun 15;421(3):141-7. [PubMed:11516429]
  4. Meliton AY, Munoz NM, Liu J, Lambertino AT, Boetticher E, Myo S, Myou S, Zhu X, Johnson M, Leff AR: Blockade of LTC4 synthesis caused by additive inhibition of gIV-PLA2 phosphorylation: Effect of salmeterol and PDE4 inhibition in human eosinophils. J Allergy Clin Immunol. 2003 Aug;112(2):404-10. [PubMed:12897749]
  5. Brogden RN, Faulds D: Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Allergol Immunopathol (Madr). 1992 Mar-Apr;20(2):72-84. [PubMed:1359777]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name
ADRB3
Uniprot ID
P13945
Uniprot Name
Beta-3 adrenergic receptor
Molecular Weight
43518.615 Da
References
  1. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN: Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):151-9. Epub 2004 Jan 17. [PubMed:14730417]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:31